05:16 PM EDT, 10/09/2024 (MT Newswires) -- Stoke Therapeutics ( STOK ) filed a registration statement with the US Securities and Exchange Commission Wednesday covering the potential sale of several securities from time to time in one or more offerings.

The filing covers common stock, preferred stock, debt securities, warrants, subscription rights and units.

Stoke Therapeutics ( STOK ) said it intends to use the net proceeds from the sale of securities for general corporate purposes.

The registration statement also includes a prospectus covering the offering, issuance and sale of up to $150 million of the company's common stock that may be issued and sold under a sales agreement with Cantor Fitzgerald.

The company said it intends to use any net proceeds from the sale of securities towards research, development of clinical and manufacturing processes, and the production of its product candidates, as well as for working capital, capital expenditures, and general corporate purposes.

Price: 11.88, Change: -0.07, Percent Change: -0.59